TOGGLE MENU TOGGLE SEARCH HOME INVESTORS Newsroom PRESS RELEASES EVENTS PRESENTATIONS Showing 1 to 7 of 78 press releases LATEST PRESS RELEASE Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference 23 November 2021 LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today READ FULL STORY Freeline to Participate in Stifel 2021 Virtual Healthcare Conference 10 November 2021 LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today READ FULL STORY Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results 09 November 2021 Freeline today announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs. The Company also announced that Pamela Foulds, MD has been appointed as Chief Medical Officer (CMO) and reported financial results for the third quarter of 2021. READ FULL STORY Freeline Therapeutics to Present FLT180a Data at the 2021 ASH Annual Meeting 04 November 2021 LONDON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today READ FULL STORY Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 03 November 2021 LONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today READ FULL STORY Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease 09 September 2021 Freeline Therapeutics today announced that both the U.S. Food and Drug Administration (“FDA”) and European Commission (“EC”) have granted Orphan Drug Designation for FLT201 for the treatment of Gaucher disease. Clinical trial site initiation on track by year end. READ FULL STORY Freeline to Participate in Upcoming Investor Conferences in September 2021 07 September 2021 Freeline today announced that it will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference and the Morgan Stanley 19th Annual Global Healthcare Conference. READ FULL STORY Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next For all media enquiries please get in touch media@freeline.life Get in touch T. Telephone: +44 (0)1438 906870 E. Email: contact@freeline.life Follow us on our social channels About us Innovation Patients & families Healthcare professionals Careers Investors Contact Terms of use Privacy Notice Accessibility Cookie Policy ©2021 Freeline